• NUZ-001 and its metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish Huntington's disease model
• Treatment prevented developmental and morphological abnormalities, protected against neuronal cell death, and restored BDNF expression
• Neurizon plans to initiate additional validation studies in mammalian Huntington's disease models

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) has announced new preclinical data demonstrating significant neuroprotective effects of NUZ-001 and its active metabolite, NUZ-001 Sulfone, in a zebrafish model of Huntington's disease (HD). In this HD disease model, the targeted knockdown of the Htt (huntingtin) protein mRNA triggers characteristic HD-related deficits, including increased cell death, morphological malformations, impaired haemoglobin production, and reduced expression of brain-derived neurotrophic factor (BDNF). Treatment with NUZ-001 or NUZ-001 Sulfone following Htt knockdown prevented developmental and morphological abnormalities, attenuated neuronal cell death, restored the delayed production of haemoglobin, and rescued BDNF expression, providing evidence of their potential to counteract early neurodegenerative damage. These findings reinforce NUZ-001's potential as a platform therapy targeting core neurodegenerative mechanisms common to multiple diseases. Neurizon plans to advance additional preclinical studies in mammalian models of Huntington's disease as part of its broader strategy to expand the therapeutic applications of NUZ-001 into other progressive neurological disorders with high unmet need.

Neurizon plans to initiate additional validation studies in mammalian models of Huntington's disease as part of its broader strategy to expand the therapeutic applications of NUZ-001 into other progressive neurological disorders with high unmet need.